Document is current
Any future updates will be listed below
-
Authors
Bass, E. J. http://orcid.org/0000-0002-4923-572X
Pantovic, A.
Connor, M. J. http://orcid.org/0000-0003-4033-7508
Loeb, S. http://orcid.org/0000-0003-3933-9207
Rastinehad, A. R.
Winkler, M. http://orcid.org/0000-0002-2553-5816
Gabe, Rhian http://orcid.org/0000-0002-0273-3094
Ahmed, H. U. http://orcid.org/0000-0003-1674-6723
-
Funding
Funding for this research was provided by:
Wellcome Trust (204998/Z/16/Z)
- License Information
-
More Information
Article History
Received: 10 February 2021
Revised: 10 August 2021
Accepted: 20 August 2021
First Online: 21 September 2021
Competing interests
: HUA’s research is supported by core funding from the United Kingdom’s National Institute of Health Research (NIHR) Imperial Biomedical Research Centre. HUA currently receives funding from the Wellcome Trust, Medical Research Council (UK), Cancer Research UK, Prostate Cancer UK, The Urology Foundation, BMA Foundation, Imperial Health Charity, NIHR Imperial BRC, Sonacare Inc., Trod Medical and Sophiris Biocorp for trials in prostate cancer. HUA was a paid medical consultant for Sophiris Biocorp in the previous 3 years. HUA receives fees for proctoring in cryotherapy (Boston), Rezum (Boston) and HIFU (Sonacare Inc). SL is supported by the Prostate Cancer Foundation. RA receives research support from Philips Healthcare.
